Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2068.24% is 44% below its 4-year average of -1432.23%, around the middle of its 4-year range (-3419.52%–-822.27%).
13.45% below its 12-month average of -1822.97%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2022 (2022-09-30): -3419.52%.
EBITDA MARGIN
-2068.24%
EBITDA MARGIN AVG TTM
-1822.97%
EBITDA MARGIN AVG 3Y
-1440.08%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-13.45%
CURRENT VS 3Y AVG
-43.62%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
KALA BIO, Inc.
Market Cap
$7.16M
EBITDA Margin
-2068.24%
TTM Avg
-1822.97%
3Y Avg
-1440.08%
5Y Avg
N/A
Market Cap
$7.27M
EBITDA Margin
-1839.87%
TTM Avg
-1245.27%
3Y Avg
-1681.64%
5Y Avg
-1341.06%
Market Cap
$6.98M
EBITDA Margin
-3822.36%
TTM Avg
-2499.82%
3Y Avg
-7123.25%
5Y Avg
-7123.25%
Market Cap
$7.23M
EBITDA Margin
3.56%
TTM Avg
3.56%
3Y Avg
3.56%
5Y Avg
3.56%
Market Cap
$7.25M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
Market Cap
$6.99M
EBITDA Margin
-430.70%
TTM Avg
-678.73%
3Y Avg
-962.21%
5Y Avg
-5357.45%
Market Cap
$6.75M
EBITDA Margin
-4847.72%
TTM Avg
-2918.14%
3Y Avg
-1630.06%
5Y Avg
-1069.46%
Market Cap
$6.66M
EBITDA Margin
-9012.26%
TTM Avg
-10323.55%
3Y Avg
-8965.35%
5Y Avg
-8208.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| KALA BIO, Inc. (KALA) | $7.16M | -2068.24% | -1822.97% | -1440.08% | N/A |
| Longeveron Inc. (LGVN)vs › | $7.27M | -1839.87% | -1245.27% | -1681.64% | -1341.06% |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | -3822.36% | -2499.82% | -7123.25% | -7123.25% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.23M | 3.56% | 3.56% | 3.56% | 3.56% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -0.29% | -74.83% | -125.41% | -344.12% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | -430.70% | -678.73% | -962.21% | -5357.45% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.91M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.75M | -4847.72% | -2918.14% | -1630.06% | -1069.46% |
| Aclarion, Inc. (ACON)vs › | $6.66M | -9012.26% | -10323.55% | -8965.35% | -8208.29% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.50M | -10.17% | -10.02% | -12.29% | -11.98% |
Gross Margin
0.0%
EBITDA Margin
-2068.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2022-09-30 | -3419.52% |
| 2022-06-30 | -1259.48% |
| 2022-03-31 | -2223.98% |
| 2021-12-31 | -1389.60% |
| 2021-09-30 | -822.27% |
| 2021-06-30 | -924.29% |
| 2021-03-31 | -859.34% |
| 2020-12-31 | -1262.51% |
| 2020-09-30 | -1132.30% |
| 2020-06-30 | -2470.23% |
| 2020-03-31 | -1813.45% |
| 2019-12-31 | -1652.71% |
| 2019-09-30 | -1470.78% |
| 2019-06-30 | -1078.85% |
| 2019-03-31 | -1691.41% |
